FASEB SRC on Acute Kidney Injury: from beside to bench (and back again)

6.项目总结/摘要 急性肾损伤（阿基）是一个日益普遍的全球性问题，对患者有重大影响。 死亡率和发病率，包括进行性慢性肾病（CKD）风险显著增加。阿基是 也是基础和临床研究的活跃领域。尽管如此，还没有确切的治疗方法表明， 加速阿基患者的恢复或预防进展为CKD。这有很多原因， 但一个主要因素是缺乏有效的合作管道之间的板凳研究人员研究 治疗阿基的机制和新的治疗方法，以及研究人类疾病的临床科学家 并实施假设检验临床试验，以评估阿基患者的新疗法。然而，在这方面， 除了美国肾脏病学会（American Society of Nephrology）的年度科学会议外， 促进临床和基础科学阿基研究界直接交流想法的论坛 在学术界和工业界。因此，这次新会议的概念是发展科学的 从板凳到床边的互动和合作，并以此为论坛， 培养一批经过培训的研究人员，以更加转化的方式思考阿基问题。 为了实现这一目标，组织者设计了一个为期三天半的FASEB科学研究会议。 来自学术医学和工业界的专家被邀请提供关于关键，主题 阿基的基础和临床科学研究方面，以及药物和 阿基的治疗进展。这也将提供第一个以证据为基础的论坛，讨论新的 研究人类阿基的方法，并开发更好的临床前模型，以反映观察到的细胞 和人类阿基的分子异质性。我们预计，这次会议将吸引调查人员， 来自学术界、工业界和政府机构的学员，参与阿基研究的不同方面， 因此，这将为促进这些利益攸关方之间新的协作互动提供一个独特的机会。

6. Project Summary/Abstract Acute kidney injury (AKI) is an increasingly prevalent worldwide problem that has a significant impact on patient mortality and morbidity, including a marked increased risk of progressive chronic kidney disease (CKD). AKI is also an active area of basic and clinical research. Despite this, no therapies have been definitively shown to accelerate recovery or prevent progression to CKD in patients with AKI. There are a number of reasons for this, but a major factor is the lack of effective collaborative pipelines between bench researchers studying the mechanisms and new therapeutic approaches to treat AKI, and clinical scientists studying the human disease and implementing hypothesis testing clinical trials to evaluate new therapeutics in patients with AKI. However, aside from the annual scientific meeting of the American Society of Nephrology (ASN), there are few established forums that promote direct exchange of ideas across the clinical and basic science AKI research communities in academia and industry. The concept of this new conference is therefore to develop scientific interactions and collaborations across the bench to bedside divide, and to use this as a forum to help develop a pipeline of investigators trained to think in a more translational way about the problem of AKI. To achieve this, the organizers have designed a three and a half day FASEB Scientific Research Conference. Experts from academic medicine and industry have been invited to provide state of the art talks on key, topical aspects of research in both the basic and clinical science of AKI, as well as recent advances in drug and therapeutic development for AKI. This will also provide the first evidence-based forum to discuss new approaches to study human AKI, and to develop better pre-clinical modeling that reflects the observed cellular and molecular heterogeneity of AKI in humans. We anticipate that this meeting will attract investigators and trainees from academia, industry and government agencies involved in different aspects of AKI research, and as such will provide a unique opportunity to foster new collaborative interactions between these stakeholders.